Houston, Texas, USA, November 13, 2026
Sino Biological, Inc. has announced the launch of 4RISE™, a high-throughput wet-lab validation service designed to accelerate AI-driven drug discovery and protein engineering research. The new service addresses an important challenge in computational drug development: validating whether artificially designed protein binders can successfully recognise and bind to their intended biological targets under experimental conditions. As artificial intelligence increasingly supports the design of antibodies, mini-proteins and other therapeutic candidates, reliable laboratory validation has become essential for translating computational predictions into experimentally supported discoveries. Through 4RISE™, Sino Biological aims to connect AI-based protein design with rapid experimental testing by providing cell-free protein expression, high-throughput binding analysis and structured experimental data. The platform combines its proprietary XPressMAX™ cell-free protein synthesis technology with advanced analytical systems to deliver protein expression results within approximately three hours and target-binding data within three days. The service also provides real-time access to structured binding information through an application programming interface (API), enabling researchers to incorporate experimental findings into subsequent computational analysis and protein design workflows. This launch represents an important development in the growing intersection of biotechnology, laboratory automation and artificial intelligence.
4RISE Accelerates Protein Expression and Binding Validation
One of the major features of the 4RISE™ platform is its ability to support rapid protein production and experimental validation. Using the XPressMAX™ cell-free protein synthesis platform, Sino Biological can produce recombinant proteins in approximately three hours, with reported expression success rates exceeding 99% in established workflows. The technology supports multiple protein formats, including mini-proteins, VHH antibody fragments, single-chain variable fragments (scFv), Fab fragments, enzymes and cytokines. This capability enables researchers to move AI-designed protein candidates into experimental testing without relying entirely on conventional cellular expression workflows. Following protein synthesis, 4RISE™ uses advanced analytical technologies to assess target-binding performance, binding affinity and interaction kinetics. These technologies include high-throughput surface plasmon resonance (SPR) systems developed by Carterra, Biacore SPR technology and the Octet biolayer interferometry platform. By combining rapid protein expression with binding analysis, the service aims to provide experimentally generated data directly from candidate protein sequences within three days. The resulting structured datasets can be accessed through an API, allowing research teams to integrate experimental observations into AI models and subsequent design iterations.
Four Screening Workflows Support AI Protein Design
The 4RISE™ service offers four specialised workflows designed to address different requirements in AI-assisted ligand discovery and protein engineering. The rapid hit discovery workflow identifies potential binding mini-proteins and VHH antibody fragments through screening of crude expression supernatants. Comparative ligand screening evaluates purified candidates under standardised conditions, helping researchers rank potential molecules according to their binding performance. Affinity and kinetic characterisation provides quantitative measurements of binding strength and interaction behaviour, supporting the selection and optimisation of promising lead candidates. The specialised ligand expression and validation workflow supports different protein formats through mammalian expression and customised binding analysis. Beyond initial target-binding assessment, Sino Biological also offers an expanded analytical package comprising more than 20 developability assays, over 1,000 protein bioactivity assays and more than 10 cell-based functional assays. These additional testing capabilities help researchers investigate protein stability, biological activity and functional performance. Such assessments are important because successful target binding alone does not guarantee that a protein candidate will become a viable therapeutic molecule. Evaluating multiple development characteristics can help identify potential limitations earlier in the discovery process and support more informed decisions about candidate optimisation.
Sino Biological Strengthens AI-Based Drug Discovery
The launch of 4RISE™ builds on Sino Biological’s experience supporting biotechnology companies and research organisations involved in AI-assisted antibody discovery, de novo ligand design and computational protein engineering. The company reports that its wet-lab validation capabilities have supported research published in scientific journals including Science, Nature Communications and Scientific Reports. By providing integrated protein expression, binding validation and functional testing services, Sino Biological aims to help researchers reduce experimental turnaround times and improve the efficiency of protein discovery programmes. The service is particularly relevant to pharmaceutical and biotechnology organisations developing AI-designed therapeutic antibodies, engineered protein binders and next-generation biologics. Access to high-quality experimental data can help computational research teams evaluate predicted binding interactions, identify promising candidates and refine subsequent design strategies. The availability of structured data through API integration also supports the development of more connected computational and experimental research workflows. 4RISE™ highlights the growing role of high-throughput laboratory services in transforming AI-generated molecular designs into experimentally validated biotechnology candidates. As AI-driven drug discovery continues to expand, platforms combining computational design with reliable laboratory evidence could become increasingly important in accelerating early-stage pharmaceutical research and therapeutic development.
Source: Sino Biological press release



